Compass Therapeutics (Nasdaq: CMPX) will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 study of tovecimig (a DLL4 x VEGF-A bispecific antibody) plus paclitaxel in advanced biliary tract cancer.
Dial-in numbers and a webcast URL are provided; a replay and accompanying presentation will be available for 90 days on the company’s Investors Events page.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CMPX
-64.41%
15 alerts
-64.41%News Effect
+7.0%Peak Tracked
-9.5%Trough Tracked
-$1.78BValuation Impact
$985.98MMarket Cap
1.2xRel. Volume
On the day this news was published, CMPX declined 64.41%, reflecting a significant negative market reaction.
Argus tracked a peak move of +7.0% during that session.
Argus tracked a trough of -9.5% from its starting point during tracking.
Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
This price movement removed approximately $1.78B from the company's valuation, bringing the market cap to $985.98M at that time.
International number1-201-493-6779Investor conference call access
Conference ID13760371Call-in identifier for webcast
Replay window90 daysAvailability of webcast replay on company website
Market Reality Check
Price:$1.9500Vol:Volume 1,078,964 is below...
low vol
$1.9500Last Close
VolumeVolume 1,078,964 is below the 20-day average of 2,775,692 ahead of the data webcast.low
TechnicalShares at $5.21 are trading above the 200-day MA of $4.62 but 24.27% below the 52-week high.
Peers on Argus
CMPX fell 2.07% while several biotech peers like XNCR, BCAX, ORKA and TYRA also ...
1 Up
CMPX fell 2.07% while several biotech peers like XNCR, BCAX, ORKA and TYRA also traded lower, and VSTM gained 2.3%. Momentum scans flagged only ANAB moving up strongly, suggesting today’s action is more stock-specific than a broad sector rotation.
Tovecimig plus paclitaxel met primary ORR endpoint in BTC Phase 2/3 study.
Pattern Detected
Recent clinical trial announcements for CMPX have both triggered positive next-day price reactions.
Recent Company History
Over the past year, CMPX issued two notable clinical trial updates. On Apr 01, 2025, tovecimig met the primary ORR endpoint in BTC with a strong positive share reaction. On Nov 04, 2025, preclinical data for CTX-10726 at SITC also saw a modest gain. Today’s announcement of upcoming topline secondary endpoints for COMPANION-002 follows this sequence of advancing oncology data disclosures.
Historical Comparison
+9.6% avg move · In the last 12 months, CMPX released 2 clinical-trial updates, with an average next-day move of 9.62...
clinical trial
+9.6%
Average Historical Moveclinical trial
In the last 12 months, CMPX released 2 clinical-trial updates, with an average next-day move of 9.62%, showing past BTC and bispecific data have been meaningful catalysts.
Clinical news has progressed from tovecimig’s BTC primary endpoint success to broader bispecific preclinical data, and now toward reporting topline secondary endpoints from COMPANION-002.
Market Pulse Summary
The stock dropped -64.4% in the session following this news. A negative reaction despite the schedul...
Analysis
The stock dropped -64.4% in the session following this news. A negative reaction despite the scheduled data review could fit patterns where markets reassess risk ahead of pivotal oncology readouts. While prior clinical updates for CMPX averaged a 9.62% move, uncertainty around progression-free and overall survival, competitive BTC treatments, and broader biotech sentiment could weigh on shares until detailed secondary endpoint data from COMPANION-002 become available.
Key Terms
phase 2/3, bispecific antibody, dll4, vegf-a, +3 more
7 terms
phase 2/3medical
"topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study"
A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.
bispecific antibodymedical
"tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel"
A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.
dll4medical
"tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination"
DLL4 is a human signaling protein that helps cells communicate to control blood vessel growth and cell development, acting like a traffic controller that directs where and how blood vessels form. Because drugs that block or modify DLL4 can change a tumor’s blood supply or affect vascular disorders, clinical trial results or regulatory decisions involving DLL4-targeting therapies can materially affect a biotech company’s valuation and commercial prospects.
vegf-amedical
"tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination"
VEGF-A is a naturally occurring protein that acts like a growth signal for new blood vessels, helping tissues develop or repair their blood supply. It matters to investors because many drugs and diagnostics target or measure VEGF-A to treat conditions such as cancers and eye diseases, so changes in clinical trial results, regulatory decisions, or new therapies related to VEGF-A can directly affect the value and prospects of companies developing those treatments.
biliary tract cancermedical
"bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer"
Biliary tract cancer is a group of cancers that start in the bile ducts or gallbladder, the small channels and organ that carry and store the digestive fluid bile; think of it as a clogging, growing problem in a body's plumbing for digestion. For investors, it matters because diagnosis, treatment advances, or clinical trial results can rapidly affect the commercial outlook for drugs, medical devices, and related healthcare companies tied to testing, therapy sales, or reimbursement.
secondary endpointsmedical
"to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study"
Secondary endpoints are the additional outcomes measured in a clinical study beyond the main goal; they can include effects on symptoms, quality of life, safety measures, or other health indicators. For investors, they matter because positive or negative secondary results can strengthen or weaken the overall story about a treatment’s benefits and risks—like seeing not only that a car reaches its destination (primary goal) but also how comfortable and efficient the ride was (secondary findings).
paclitaxelmedical
"tovecimig ... in combination with paclitaxel in patients with advanced biliary tract cancer"
Paclitaxel is a chemotherapy drug used to treat several types of cancer; it works by binding to and “freezing” the cell’s internal scaffolding so cancer cells cannot divide and grow, much like freezing the rungs of a ladder stops climbers. It matters to investors because clinical trial results, regulatory approvals, manufacturing capacity, patent status and competition from generics or biosimilars directly affect sales, pricing and the financial outlook of companies involved in its development or supply.
AI-generated analysis. Not financial advice.
Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Conference Call and Webcast Presentation:
Date and Time: Monday, April 27, 2026 at 8:00am ET
A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the “Events” page under the Investors section of the Company’s website.
About Compass Therapeutics Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com.
When will Compass Therapeutics (CMPX) present topline secondary endpoints from COMPANION-002?
The webcast is scheduled for Monday, April 27, 2026 at 8:00am ET and includes a conference call. According to the company, the session will review topline secondary endpoints from the Phase 2/3 COMPANION-002 study for tovecimig in BTC.
How can investors access the CMPX webcast and presentation on April 27, 2026?
Investors can join via toll-free phone numbers or the webcast URL provided in the announcement. According to the company, international dial-in options and a replay accessible for 90 days are available on the Events page under Investors.
What data will Compass Therapeutics (CMPX) present about tovecimig on April 27, 2026?
The presentation will cover topline secondary endpoints from the Phase 2/3 COMPANION-002 study of tovecimig combined with paclitaxel. According to the company, the study population is patients with advanced biliary tract cancer and uses a DLL4 x VEGF-A bispecific antibody.
Will a replay of the CMPX webcast be available after the April 27, 2026 event?
Yes, a replay and the presentation will be available for 90 days after the webcast on the company’s Investors Events page. According to the company, the replay will be posted following the April 27, 2026 session.
What conference ID and phone numbers should shareholders use to join the CMPX call on April 27, 2026?
Use Conference ID 13760371 to join by phone; toll-free and international numbers are provided for the call. According to the company, toll-free 1-877-407-9716 and international 1-201-493-6779 connect to the April 27, 2026 webcast and conference call.
